TrialNephron2016

Phosphate Binding Therapy to Lower Serum Fibroblast-Growth-Factor-23 Concentrations in Chronic Kidney Disease: Rationale and Study Design of the Sevelamer on FGF23 Trial (SoFT).

Aaltje Y Adema et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.